IRD

#3329
Opus Genetics, Inc. - Common Stock
3.6 1 USD
-0.02%
Market Price
Settore: Salute
Base: USD
Valuta di Profitto: USD
Intervallo Giornaliero
3.56
3.61
Intervallo Annuale
2.82
5.81
Variazione giornaliera
-2.17%
Variazione Mensile
-2.96%
Variazione di 6 mesi
-11.52%
Variazione Annuale
-2.96%
Chiusura Precedente
3.6 9
Open
3.5 8
Minimo
3.5 6
Massimo
3.6 1
Volume
127
Apri il grafico completo

Financials

Panoramica Estratto Conto Statistiche Documents

2026

Current report, Q3 FY2026
Opus Genetics, Inc. current report, Q3 FY2026
8-K
Quarterly report, Q2 FY2026
Opus Genetics, Inc. quarterly report, Q2 FY2026
10-Q
Current report, Q2 FY2026
Opus Genetics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Opus Genetics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Opus Genetics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Opus Genetics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Opus Genetics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Opus Genetics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Opus Genetics, Inc. current report, Q2 FY2026
8-K
Quarterly report, Q1 FY2026
Opus Genetics, Inc. quarterly report, Q1 FY2026
10-Q

Opus Genetics, Inc. current report, Q1 FY2025

Full document

Opus Genetics, Inc. - Form 8-K Summary

Business Context and Reporting Period

This Current Report on Form 8-K was filed by Opus Genetics, Inc. on January 24, 2025, covering events that occurred on January 17, 2025. The filing addresses amendments to executive employment agreements for the Company's Chief Executive Officer and Chief Financial Officer.

Key Financial Metrics

The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on executive compensation arrangements and does not contain financial performance data.

Material Changes

On January 17, 2025, the Company amended the employment agreements of Dr. George Magrath (CEO) and Mr. Nirav Jhaveri (CFO) to standardize terms and enhance severance benefits in the event of a "Change in Control":

  • Severance Multiples: Increased cash severance to 1.5 times the sum of annual base salary and target bonus for Dr. Magrath, and 1.0 times for Mr. Jhaveri.
  • Health Benefits: Extended COBRA coverage to 18 months for Dr. Magrath and 12 months for Mr. Jhaveri upon qualifying termination.
  • Prorated Bonus: Dr. Magrath is now entitled to a prorated target annual bonus if terminated prior to a Change in Control.
  • Timing Window: Mr. Jhaveri's eligibility for enhanced severance now includes the three-month period prior to a Change in Control.

Guidance, Outlook, and Risks

The filing contains no financial guidance, outlook, or management commentary regarding business operations. The primary contingency described is the potential financial obligation to executives in the event of a Change in Control or qualifying termination.

Investor Verification Checklist

  • Review the full text of the Amended and Restated Employment Agreement (Exhibit 10.1) and Second Amendment (Exhibit 10.2) for specific definitions of "Change in Control" and "Qualifying Termination."
  • Verify the current annual base salary and target bonus amounts for Dr. Magrath and Mr. Jhaveri to calculate potential severance liabilities.
  • Assess the impact of these enhanced severance packages on the Company's cash reserves and future liquidity.